---
aliases:
  - RMD
---
#actor #healthcare #medtech #usa #public

ResMed -- global leader in CPAP and sleep apnea devices. GLP-1 drugs are a paradoxical tailwind/headwind: obesity reduction could reduce sleep apnea prevalence long-term, but near-term GLP-1 patients are 11% more likely to initiate CPAP therapy due to increased health awareness.

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | RMD (NYSE) |
| HQ | San Diego, CA |
| Focus | CPAP, sleep apnea, respiratory care |
| GLP-1 impact | Mixed -- short-term tailwind, long-term headwind |

## Related

- [[GLP-1 receptor agonists]] -- obesity treatment reducing sleep apnea
- [[Eli Lilly]] -- Zepbound approved for OSA
- [[Healthcare]] -- sector

*Stub -- expand when relevant*
